Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SRP-1003 IV Infusion, SRP-1003 Infusion, SRP-1003 SC Injection
SRP-1003 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| SRP-1003 IV Infusion | EXPERIMENTAL | Single or multiple doses of SRP-1003 by intravenous (IV) infusion |
| Placebo by IV Infusion | PLACEBO_COMPARATOR | Single or multiple doses of placebo by IV infusion |
| SRP-1003 SC Injection | EXPERIMENTAL | Single or multiple doses of SRP-1003 by subcutaneous (SC) injection |
| Placebo by SC Injection | PLACEBO_COMPARATOR | Single or multiple doses of placebo by SC injection |
| Name | Type | Description |
|---|---|---|
| SRP-1003 IV Infusion | DRUG | SRP-1003 by IV infusion |
| Placebo IV Infusion | DRUG | 0.9% sodium chloride (NaCl) calculated volume to match active treatment by IV infusion |
| SRP-1003 SC Injection | DRUG | SRP-1003 by SC injection(s) |
| Placebo SC Injection | DRUG | 0.9% NaCl calculated volume to match active treatment by SC injection(s) |
Key Inclusion Criteria: * Genetically confirmed diagnosis of DM1 * Clinician-assessed signs of DM1 including clinically apparent myotonia * Onset of DM1 symptoms occurred after the age of 12 years * Walk for at least 10 meters independently at screening * Participants of childbearing potential must...